Overview
On 28 June 2019, orphan designation EU/3/19/2177 was granted by the European Commission to Bayer AG, Germany, for regorafenib for the treatment of glioma.
Key facts
Active substance |
regorafenib
|
Intended use |
Treatment of glioma
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/19/2177
|
Date of designation |
28/06/2019
|
Sponsor |
Bayer AG |
Update history
Date | Update |
---|---|
December 2022 | The product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: